MEGF10 sirna

MEGF10 siRNA (Mouse)

Cat. Num. AAA8218370

• Gene Names: Megf10; Gm331; 3000002B06Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: MEGF10; MEGF10 siRNA (Mouse); Multiple epidermal growth factor-like domains protein 10; Multiple EGF-like domains protein 10; MEGF10 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: MEGF10 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1147

• Applicable Applications for MEGF10 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse MEGF10 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for MEGF10 sirna

siRNA to inhibit MEGF10 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 50233828
• NCBI GeneID: 70417
• NCBI Accession #: NP_001001979.1
• NCBI GenBank Nucleotide #: NM_001001979.2
• UniProt Accession #: Q6DIB5; Q3TLU3; Q3UG73
• Molecular Weight: 122,972 Da
• NCBI Official Full Name: multiple epidermal growth factor-like domains protein 10
• NCBI Official Synonym Full Names: multiple EGF-like-domains 10
• NCBI Official Symbol: Megf10
• NCBI Official Synonym Symbols: Gm331; 3000002B06Rik
• NCBI Protein Information: multiple epidermal growth factor-like domains protein 10
• UniProt Protein Name: Multiple epidermal growth factor-like domains protein 10
• Protein Family: Multiple epidermal growth factor-like domains protein
• UniProt Gene Name: Megf10
• UniProt Synonym Gene Names: Multiple EGF-like domains protein 10
• UniProt Entry Name: MEG10_MOUSE

Uniprot Description

MEGF10: Membrane receptor involved in phagocytosis by macrophages of apoptotic cells. Cooperates with ABCA1 within the process of engulfment. Promotes the formation of large intracellular vacuoles and may be responsible for the uptake of amyloid-beta peptides. May also function in the mosaic spacing of specific neuron subtypes in the retina through homotypic retinal neuron repulsion. Mosaics provide a mechanism to distribute each cell type evenly across the retina, ensuring that all parts of the visual field have access to a full set of processing elements. May play role in cell adhesion and motility. Is also an essential factor in the regulation of myogenesis. Controls the balance between skeletal muscle satellite cells proliferation and differentiation problably through regulation of the notch signaling pathway. Defects in MEGF10 are the cause of myopathy, early-onset, areflexia, respiratory distress, and dysphagia (EMARDD). An autosomal recessive congenital myopathy characterized by onset at birth, or early in infancy, of respiratory distress caused by diaphragmatic weakness. Additional features are dysphagia resulting in poor feeding, failure to thrive, poor head control, facial weakness, cleft palate, contractures and scoliosis. Affected individuals become ventilator-dependent, and most require feeding by gastrostomy. The disorder results in severe muscle weakness and most patients never achieve walking. Death from respiratory failure in childhood occurs in about half of patients. Muscle biopsy shows myopathic changes, replacement of myofibers with fatty tissue, small and incompletely fused muscle fibers, and variation in fiber size. Short regions of sarcomeric disorganization with few or no mitochondria (minicores) have been observed in some cases. Belongs to the MEGF family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Membrane protein, integral

Cellular Component: cell projection; membrane; integral to membrane; plasma membrane; phagocytic cup

Biological Process: regulation of muscle cell differentiation; muscle development; satellite cell proliferation; homotypic cell-cell adhesion; muscle cell development; satellite cell differentiation; regulation of skeletal muscle development; satellite cell activation; cell adhesion; recognition of apoptotic cell; phagocytosis